{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:42:26Z","timestamp":1777675346155,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Post-hoc analysis to compare the outcomes of brolucizumab 6\u2009mg vs. aflibercept 2\u2009mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After 3 monthly loading doses, brolucizumab-treated eyes (<jats:italic>N<\/jats:italic>\u2009=\u2009730) received injections every 12 weeks (q12w) or q8w if disease activity was detected. Aflibercept-treated eyes (<jats:italic>N<\/jats:italic>\u2009=\u2009729) received fixed q8w dosing. Early persistent fluid was defined as the presence of subretinal fluid and\/or intraretinal fluid up to Week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A lower proportion of brolucizumab patients had early persistent retinal fluid compared with aflibercept (11.2% (<jats:italic>n<\/jats:italic>\u2009=\u200982) vs. 19.2% (<jats:italic>n<\/jats:italic>\u2009=\u2009140)). In these patients, 34.1% of the brolucizumab-treated group achieved a\u2009\u2265\u200915 ETDRS letter gain in best corrected visual acuity (BCVA) from baseline at Week 96 compared with 20.7% of the aflibercept-treated group. Brolucizumab achieved numerically better BCVA outcomes (Week 96: brolucizumab, +6.4 letters; aflibercept, +3.7 letters) and significantly greater central subfield thickness reductions versus aflibercept from baseline through Week 96 (Week 96: \u2212202\u2009\u00b5m vs. \u2212145\u2009\u00b5m;<jats:italic>p<\/jats:italic>\u2009=\u20090.0206). Brolucizumab demonstrated an overall favourable benefit\/risk profile in this patient cohort. In their unmasked, post-hoc review, the Safety Review Committee identified two cases of retinal vasculitis and no cases of retinal vascular occlusion in the brolucizumab arm; no cases of retinal vasculitis or retinal vascular occlusion were identified in the aflibercept arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this analysis, anatomical and visual outcomes were better with brolucizumab compared with aflibercept. Brolucizumab may therefore achieve greater disease control than aflibercept in nAMD patients with early persistent retinal fluid.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41433-022-02092-5","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T05:03:48Z","timestamp":1653109428000},"page":"1242-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies"],"prefix":"10.1038","volume":"37","author":[{"given":"David R.","family":"Lally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-5133","authenticated-orcid":false,"given":"Yit C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinfemichael","family":"Gedif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Best","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hersh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Heier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"2092_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324.","journal-title":"Prog Retin Eye Res"},{"key":"2092_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1419\u201331.","journal-title":"N. Engl J Med"},{"key":"2092_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1432\u201344.","journal-title":"N. Engl J Med"},{"key":"2092_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","volume":"123","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, et al. Differential response to Anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123:1856\u201364.","journal-title":"Ophthalmology"},{"key":"2092_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"2092_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl J Med. 2011;364:1897\u2013908.","journal-title":"N. Engl J Med"},{"key":"2092_CR7","first-page":"S3","volume":"24","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Lloyd Clark W, Nielsen JS, Brill JV, Greene LS, Heggen CL, et al. Optimizing Anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24:S3\u201315.","journal-title":"J Manag Care Spec Pharm"},{"key":"2092_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2092_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963\u201376.","journal-title":"Ophthalmology"},{"key":"2092_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"2092_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"2092_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mones","year":"2021","unstructured":"Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"},{"key":"2092_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296\u2013304.","journal-title":"Ophthalmology"},{"key":"2092_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521\u20139.","journal-title":"Ophthalmology"},{"key":"2092_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond). 2020;34:2249\u201356.","journal-title":"Eye (Lond)"},{"key":"2092_CR16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","volume":"41","author":"GS Reiter","year":"2021","unstructured":"Reiter GS, Grechenig C, Vogl WD, Guymer RH, Arnold JJ, Bogunovic H, et al. Analysis of fluid volume and its impact on visual acuity in the fluid study as quantified with deep learning. Retina. 2021;41:1318\u201328.","journal-title":"Retina"}],"updated-by":[{"DOI":"10.1038\/s41433-022-02130-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02092-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:14:41Z","timestamp":1700612081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02092-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02092-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41433-022-02130-2","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41433-022-02130-2","URL":"https:\/\/doi.org\/10.1038\/s41433-022-02130-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DRL: Scientific advisory fees from Alimera Sciences, Allergan, Apellis, EyepointPharmaceuticals, Genentech, Iveric Bio, Novartis; research funding from Aldeyra Therapeutics,Annexon Biosciences, Apellis, Canon, Chengdu Kanghong, Emmes\/MacTel Project, EyepointPharmaceuticals, Iveric Bio, Kodiak Sciences, Novartis, Neurotech, Notal Vision, Optos, StealthBiotherapeutics; AL: Consultant to Allergan, Bayer HealthCare, BeyeOnics Surgical,ForSightlabs, Notal Vision, Novartis and Roche; JJA: Honoraria from Allergan, Bayer, Alcon and Novartis; YCY: Receipt of honoraria, travel reimbursement, patent royalties from Alcon, Allergan, Alimera Sciences, Bayer, Novartis, Pfizer, Thrombogenics, Heidelberg and Roche; KG: Employee of Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA; CB: Employee of Novartis Pharma AG, Switzerland; HP: Former employee of Novartis Pharmaceuticals Corporation, East Hannover, NJ, USA; RT: Alcon, Bausch and Lomb, FCI, Moria, Zeiss, Optovue, Topcon, Alimera, Allergan, Bayer, Novartis, Oculis, Genentech, Roche, Thea; JSH: Scientific advisory fees from 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Alkahest, Allegro, Allergan, Annexon, Apellis, Array, Asclepix, BVI, Eloxx, Galimedix, Genentech, Generation Bio, Gyroscope, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Ocugenix, Oculis, Ocular Therapeutix, Omeicos, Regeneron, Regenxbio, Retrotope, Santen, Scifluor, Shire, Stealth Biotherapeutix, Tyrogenex, Voyant; research funding from Aerpio, Apellis, Clearside, Genentech, Genzyme, Gyroscope, Hemera, Janssen, jCyte, KalVista, Kanghong, Novartis, Ophthotech, Regeneron, Regenxbio, Stealth, Thrombogenics, TLC","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}